• Solid Biosciences posted a GAAP net loss of $54.8 million, widening 38.8% year over year.
• GAAP operating loss widened to $57.4 million, driven by operating expenses of $57.4 million, up 37.6% year over year.
• GAAP R&D expense climbed to $44.3 million, up 36.6%, on higher SGT-003 manufacturing and clinical costs.
• GAAP G&A expense rose to $13.1 million, up 41.4%, mainly on higher personnel-related costs.
• Cash, cash equivalents and available-for-sale securities totaled $377.7 million at June 30, 2026; runway expected into mid-2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-337935), on August 06, 2026, and is solely responsible for the information contained therein.